The Delhi High Court overturned the Patent Office’s refusal of Honeywell’s patent amendments, holding that the changes were within the scope of the original claims. This ruling affirms the importance of fair and thorough examination of patent applications under Indian law.
Read more about Delhi High Court Reverses Patent Office Decision: Honeywell’s Amendments UpheldCategory: Patents
Indian Patent and Design Statistics 2024 (June 7th to 14th)
The report analyses Indian patent and design statistics for the week of 7th to 14th June 2024, including city-wise publication and grant trends. It offers factual insights into patent and industrial design activity, based on official data and objective analysis.
Read more about Indian Patent and Design Statistics 2024 (June 7th to 14th)Inventive Step Assessment: To be Anchored in Knowledge of a Person with Ordinary Skill on the Priority Date
The Delhi High Court’s decision highlights the requirement for an objective inventive step assessment anchored in the knowledge of a person skilled in the art at the priority date. The ruling emphasises the need for detailed analysis and avoidance of hindsight in patent examinations.
Read more about Inventive Step Assessment: To be Anchored in Knowledge of a Person with Ordinary Skill on the Priority DateIndian Patent and Design Statistics 2024 (May 31st to June 7th)
The report analyses Indian patent and design statistics for 31 May to 7 June 2024, with city-wise and yearly data on applications, grants, and registrations. It provides a factual overview for professionals seeking updated intellectual property trends in India.
Read more about Indian Patent and Design Statistics 2024 (May 31st to June 7th)Boehringer secures Patent Injunction for its Diabetes Drug – Empagliflozin
The Himachal Pradesh High Court has granted Boehringer Ingelheim an interim injunction against Eris Lifesciences, preventing the manufacture and sale of Empagliflozin during the suit. The case provides insights into the judicial approach towards pharmaceutical patent disputes in India.
Read more about Boehringer secures Patent Injunction for its Diabetes Drug – EmpagliflozinIndian Patent and Design Statistics 2024 (May 24th to 31st)
This report analyses Indian patent and design statistics for 24th to 31st May 2024, highlighting weekly and yearly trends, city-wise data, and industrial design registrations. The information is compiled by BananaIP’s expert team with a focus on clarity and factual accuracy.
Read more about Indian Patent and Design Statistics 2024 (May 24th to 31st)Patent examination should not kill the scientific temper of an inventor
The Madras High Court set aside the rejection of Industeel France’s patent application, stressing the need for fair and consistent patent examination. The judgment highlights the importance of protecting inventors’ scientific temper and ensuring time-bound decisions under Indian patent law.
Read more about Patent examination should not kill the scientific temper of an inventorNew claims, Old claims, and Claim Amendments: Section 59 of the Patents Act
This post examines a Madras High Court ruling on Section 59 of the Patents Act regarding patent claim amendments. The Court clarified procedural requirements and applicant rights during the patent examination process in India.
Read more about New claims, Old claims, and Claim Amendments: Section 59 of the Patents ActIndian Patent and Design Statistics 2024 (May 17th to 24th)
This report analyses Indian patent and design statistics for May 17th to 24th, 2024, focusing on applications, grants, and city-wise trends. Authored by BananaIP, it offers a neutral and factual overview for legal and IP professionals.
Read more about Indian Patent and Design Statistics 2024 (May 17th to 24th)Monoclonal antibodies and Patents – How the Madras High Court interpreted Section 3(c)
The Madras High Court clarified the interpretation of Section 3c regarding patent eligibility of monoclonal antibodies in India. The Court held that synthetic antibodies may be patentable if they demonstrate novelty or technical advancement.
Read more about Monoclonal antibodies and Patents – How the Madras High Court interpreted Section 3(c)